Advisors

John has had a long-standing and deep interest in the biological sciences since childhood. In pursuit of this passion, he obtained a B.A. in his home state from the University of Delaware with a double major in Biology and Psychology. He then immediately entered an advanced program and earned a Ph.D. in Physiology from the UT Southwestern Medical Center in Dallas, TX where he focused on ion transport systems in the heart and in immune cells. Afterwards he refined his research focus further by
pursuing post-doctoral studies in Immunology, first at National Jewish Health in Denver, CO and then at the DNAX Research Institute (Palo Alto, CA). He initiated an engaging period in pharmaceutical discovery and development at Syntex Research in Palo Alto and also held an Adjunct Professor position in Cancer Biology at nearby Stanford University. His career then continued as Director, Vice President and CSO at several biotechnology companies (Cadus, Axiom, Novasite, Cytori Therapeutics, Advanced Molecular Design, 82 Biosciences), the last two of which he co-founded. Most recently he concluded a position as the VP of R&D and Head of Emerging Technologies at BioLegend, Inc, a successful biological reagents company, where he managed new product selection and development and also the importation and optimization of several novel reagent technologies for advanced biological research.

Currently he is co-founder and Chief Scientific Officer of Vivreon Biosciences, LLC, where they aggressively pursue cures for chronic inflammatory conditions. He also has recently co-authored multiple clinical research papers for Direct Biologics that report on the safety and efficacy of a novel, safe and effective human bone marrow mesenchymal stem cell derived extracellular vesicle preparation (ExoFlo TM ) that is currently in late-stage clinical development for multiple indications. He is also a co- founder and current Board Chair for New England Animal Health, a non-profit dedicated to establishing the first centralized and stable supply repository of highly qualified biological research reagents, carefully selected from around the world, to be used by researchers for vaccine development and disease monitoring in food animals critical to health and security in developing nations.

Dr. Ransom is thrilled to be able to help bring the unique technologies at Stabilux forward into the realm of disruptive products that can solve several bottlenecks currently impeding biomedical progress.